‘The blue inhaler is a killer,’ says expert


asthma reliever puffer on its side
There is “mounting evidence” that it’s time to reduce reliance on short-acting beta2 agonists, say experts A recent controlled trial published in the New England Journal of Medicine found treatment with short-acting beta2 agonists (SABA) alone was inferior to other approaches in terms of asthma attacks. The same study showed as needed combined inhaled corticosteroids

This content is restricted. If you have already registered on the AJP website please login below, Or you can Register for free.

Forgot Password?Why do I need to login & stay in?

Previous Showing the way
Next Reducing the risk of violence